NSE
Glenmark Pharmaceuticals LimitedGLENMARK
Glenmark Pharmaceuticals is a research-led branded-generics company.
| Key products | Dermatology, respiratory and oncology generics & specialty; APIs. |
|---|---|
| Geography | India, US, Europe, emerging markets. |
| Competitors | Cipla, Sun Pharma, Lupin. |
AI-generated overview — verify before relying on it.
Net institutional flow
No institutional deals
Institutional buyers
0 in / 0 out
High-impact filings
0 · tilt Neutral
Next corporate action
Interim Dividend - Rs 2.50 Per Share
ex 2025-10-03
Competitive landscape — the read
vs mapped peers| # | Company | Inst. flow ₹Cr | Deals | Hi-impact | Filing mom. | Buzz | News |
|---|---|---|---|---|---|---|---|
| 1 | CIPLA | +₹1,527.1 Cr | 39 | — | +1 | +10 | 34 |
| 2 | ALKEM | +₹103.5 Cr | 33 | — | — | -2 | 6 |
| 3 | GLENMARKThis | +₹0 Cr | 6 | — | — | — | — |
| 4 | DRREDDY | +₹0 Cr | 4 | — | — | +15 | 32 |
| 5 | SUNPHARMA | +₹0 Cr | 6 | — | +2 | +9 | 29 |
| 6 | TORNTPHARM | +₹0 Cr | 2 | — | — | — | — |
| 7 | LUPIN | +₹0 Cr | 4 | — | — | — | — |
| 8 | ZYDUSLIFE | +₹0 Cr | 1 | — | — | — | — |
| 9 | AUROPHARMA | +₹0 Cr | 2 | — | — | — | — |
Ranked by net institutional flow (buys − sells, ₹Cr). Filing momentum = bullish − bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.
Timeline — GLENMARK day by day
- 2026-06-11FilingGlenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 11, 2026, titlePress Release
- 2026-06-09FilingGlenmark Pharmaceuticals Limited has informed the Exchange about Investor PresentationInvestor Call
- 2025-10-03ActionInterim Dividend - Rs 2.50 Per ShareDividend
- 2025-09-15ActionDividend - Rs 2.50 Per ShareDividend
- 2025-07-11BulkBUY · ₹328.1 CrGRAVITON RESEARCH CAPITAL LLP
- 2025-07-11BulkSELL · ₹328.3 CrGRAVITON RESEARCH CAPITAL LLP
Merged from deals, filings, corporate actions and news — newest first. Scope the deal/action portion with the period chips below.
Filings that matter
- 2Press ReleaseNeutral
a press release dated Jun 11, 2026, titled "Glenmark Launches Winlevi® (clascoterone) 10 mg/g cream in Key European Markets for the Treatment of Acne Vulgaris".
Source PDF → - 3
2 deals · 2025-07-11 → 2025-07-11
| Date | Counterparty | Investor type | Side | Value |
|---|---|---|---|---|
| 2025-07-11 | GRAVITON RESEARCH CAPITAL LLP | Prop / churn | BUY | ₹328.1 Cr |
| 2025-07-11 | GRAVITON RESEARCH CAPITAL LLP | Prop / churn | SELL | ₹328.3 Cr |
2 deals in the selected window — corporate actions are scoped to the same period. ~2 years of history available.
Results & transcripts
Financial results
None yet.
News & chatter on GLENMARK
RSS News
0No recent news.
Google News RSS — links open the source.
The Dispatch
0No articles yet.
Our coverage.
No Reddit chatter.
r/ posts mentioning the company.
Twitter / X
0No posts.
Posts mentioning the company.